Two new biotech drugs for colorectal cancer, Avastin and Erbitux
March 2004
Two new biotech drugs for colorectal cancer, Avastin and Erbitux, are making news.
Avastin (bevacizumab) is the first of a new kind...an angiogenesis inhibitor. It slows the growth of blood vessels that tumors need to grow.
It's approved for metastatic colorectal cancer...in combination with traditional chemotherapy. Avastin slows progression...and improves survival by about 5 months.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote